<SEC-DOCUMENT>0000000000-24-008222.txt : 20250807
<SEC-HEADER>0000000000-24-008222.hdr.sgml : 20250807
<ACCEPTANCE-DATETIME>20240719173606
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000000000-24-008222
CONFORMED SUBMISSION TYPE:	UPLOAD
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20240719

FILED FOR:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Jyong Biotech Ltd.
		CENTRAL INDEX KEY:			0001954488
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			E9

	FILING VALUES:
		FORM TYPE:		UPLOAD
		SEC FILE NUMBER:	377-07118

	BUSINESS ADDRESS:	
		STREET 1:		23F-3, NO.95, SEC. 1, XINTAI 5TH RD.
		STREET 2:		XIZHI DIST.
		CITY:			NEW TAIPEI CITY
		STATE:			F5
		ZIP:			221
		BUSINESS PHONE:		(8862) 27325205

	MAIL ADDRESS:	
		STREET 1:		23F-3, NO.95, SEC. 1, XINTAI 5TH RD.
		STREET 2:		XIZHI DIST.
		CITY:			NEW TAIPEI CITY
		STATE:			F5
		ZIP:			221
PUBLIC REFERENCE ACCESSION NUMBER:		0001213900-24-019473
</SEC-HEADER>
<DOCUMENT>
<TYPE>LETTER
<SEQUENCE>1
<FILENAME>filename1.pdf
<TEXT>
<PDF>
begin 644 filename1
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M3!0'_S5GFYV<!B&->>8AA AUP^Q.=W7)5 E%4-5A%/$0*@3)GE1=LYUXE P
M0]X,$ M2R;0II8'/IB&(EWSA$=BN0&Y670TQE_)1UKIEOWQ8 SGNKX@D]^^N
MV8-ZE TEF16=,0"1DC;0M=4.88MZVO%1RE?^^#'/KX'H%".RLFN0@!AD*?>P
MR!DH.SX&)1"?"9&O(W!'V1&1IR&91X&5+TZRHI+.USS4^8(:LF7,EWZOGR&/
M1CQ(8'!524.I0=**%K"*8@>:INH]"HB;80Q]YO>PE'-^S5K\ZRB*1T?.&?[[
MXZ?9'$][&DZ->)ZR_2Q-5CP)C_5L_2K,;!G8%\TOJ7:T^+9AP+46ZX7@6Z-
MH6 5")E!#K%PI$WZC=A!DMJW-7@6$T!;"Y%"O*5P8E)ULC0--(5\*JP"NL0U
M[;!%$=:Z^)MJA"<KZV!%#<^B/E@%?,)O2B,JYSVU5@TM\'(VLM7&<;;NBMTT
M.,D\T-8ZV5HLIQ2&-1(5),R!59 2C'Y4W,!0,I8" "D +_GQ3^1Y;76?,S
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MWL0FY3Q:Q:'+ARS[3O7<L@Y(0V#:_95/Y.?UC;A_%Z8=^"*4GBY=CY*(.@W
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M+B'8/#P\/&RQ>8@"V&9D1(O\'#5\?'S<W]^G5TB4C*.DFTG5-+#BJ#7'OM&
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M!/M&OIHH Q<4F].LFN/SI'"T>=(#<WC347N5+L4Q9[XOZL>PWY:#=I'?KBD
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M>[:,VKV[!3RW.;NWHR0"T1@"*-7)WJ_/OB>3%Z_T:FH=]:"-96E#KUW,V\\
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M*L6*@+=7? B8\7+NU=MZPL423>_TS82D:3#Q1NA;)K=&NA"1OXJZTF=M4E=
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M]43ZI?3RV4@@3ZJ/=H@"OS8TYSOT^0C52"7#8ZW)"Q/?GZ4+W=G']\[Z;Z+
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M$.EF\@V+\7RYDR$QFQ"C7T0-87%!\,\4/=@1WQ;#7(B(B(B(B(B<)%;]1(=
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M:" Q-#(X/CYS=')E86T*>)SMP8$     PR!_ZMW@!%4!
M
M
M
M
M
M
M
M                  #/ %&5NID*96YD<W1R96%M"F5N9&]B:@IX<F5F"C @
M,C8*,# P,# P,# P," V-34S-2!F( HP,# P,# Y,3@V(# P,# P(&X@"C P
M,# P,3 P-#(@,# P,# @;B *,# P,# P.3(S,2 P,# P,"!N( HP,# P,# Q
M,S(W(# P,# P(&X@"C P,# P,# P,34@,# P,# @;B *,# P,# P.38X,2 P
M,# P,"!N( HP,# P,# Y-S<Q(# P,# P(&X@"C P,# P,#,U,S@@,# P,# @
M;B *,# P,# P,38R-" P,# P,"!N( HP,# P,# Q-#DR(# P,# P(&X@"C P
M,# P,#DY-3$@,# P,# @;B *,# P,# Q,#$R," P,# P,"!N( HP,# P,# U
M-S<X(# P,# P(&X@"C P,# P,#,X,C$@,# P,# @;B *,# P,# P,S8X.2 P
M,# P,"!N( HP,# P,# Y-#DY(# P,# P(&X@"C P,# P,#<Y,34@,# P,# @
M;B *,# P,# P-C V,B P,# P,"!N( HP,# P,# U.3,Q(# P,# P(&X@"C P
M,# P,#DU.3 @,# P,# @;B *,# P,# P.3 S,R P,# P,"!N( HP,# P,# X
M,C P(# P,# P(&X@"C P,# P,#@P-C@@,# P,# @;B *,# P,# P.3@V," P
M,# P,"!N( HP,# P,#,U,S@P(# P,# P(&X@"G1R86EL97(*/#PO240@6SQA
M,F,W-&1B8F-A93=E8V0V-&0R964P,&8T.&%F.#EE-CX\83)C-S1D8F)C864W
M96-D-C1D,F5E,#!F-#AA9C@Y938^72]);F9O(#,@,"!2+U)O;W0@,2 P(%(O
M4VEZ92 R-CX^"B5I5&5X="U#;W)E+3<N,BXT"B5I5&5X="UP9&9(5$U,+30N
:,"XT"G-T87)T>')E9@HS-3DP,PHE)45/1@H!

end
</PDF>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
                                                           July 19, 2024

Fu-Feng Kuo
Chief Executive Officer
Jyong Biotech Ltd.
23F-3, No. 95, Section 1, Xintai 5th Road
Xizhi District, New Taipei City
Taiwan, 221

       Re: Jyong Biotech Ltd.
           Amendment No. 2 to Registration Statement on Form F-1
           Filed June 21, 2024
           File No. 333-277725
Dear Fu-Feng Kuo:

     We have reviewed your amended registration statement and have the
following
comments.

       Please respond to this letter by amending your registration statement
and providing the
requested information. If you do not believe a comment applies to your facts
and circumstances
or do not believe an amendment is appropriate, please tell us why in your
response.

       After reviewing any amendment to your registration statement and the
information you
provide in response to this letter, we may have additional comments. Unless we
note otherwise,
any references to prior comments are to comments in our May 31, 2024 letter.

Amendment No. 2 to Registration Statement on Form F-1
Prospectus Summary
Overview, page 1

1.     Please revise the discussion of your current plans to develop MCS-2
(API-2) to clarify the
       FDA   s concerns communicated on pages 1-2 of its February 23, 2024
correspondence,
       which you provided in response to our May 31, 2024 request. The
communication
       indicates that your proposed plan to conduct one phase 1 study and one
phase 3 efficacy
       study using your product containing API-2 faces significant challenges.
Please update
       your Summary to briefly describe the FDA   s concerns and provide a more
fulsome
       discussion of these concerns in the Business section.
2.     We note your response to prior comment 1 and reissue in part. Please
revise your
       disclosure throughout your filing to remove language indicating that the
comparability is
 July 19, 2024
Page 2

       an inevitable conclusion, such as "[O]nce the US FDA is convinced about
the
       comparability of API-1 and API-2...." You may discuss what happens if
you are able to
       demonstrate comparability, but you must indicate that to date you have
not been able to
       do so and what your path forward is if you are unable to demonstrate
comparability.
       Please also state if you have had discussions with the Taiwan regulator
about the
       substitution of API-2 for API-1 in MCS-2. If you have not, or if the
Taiwan regulator also
       requires comparability studies, it is not appropriate to indicate that
you have completed
       Phase 1 studies for PCP (API-1).
3.     In response to prior comment 1 you state that you are preparing CMC
information for
       API-2, are planning to establish comparability between API-1 and API-2,
and once the
       FDA is convinced about the comparability you will then initiate the
MCS-2 Phase III and
       Phase I PK study. Please revise your disclosure to state that you
currently do not have an
       API-2 supplier and that you cannot proceed until you identify a supplier
of API-2. Please
       also include such disclosure throughout your prospectus where you
discuss PCP,
       including but not limited to pages 6, 109, and 124. Additionally include
a risk factor
       discussion addressing the potential consequences if the FDA does not
agree that API-1 is
       comparable to API-2.
4.     In response to prior comment 4 you state that you plan to demonstrate
that API-1 and
       API-2 are comparable to be able to rely on all prior trials. You also
state that due to a
       failed MCS-2-US-a study you will conduct an additional Phase III pivotal
study in the US
       using API-2. Please clarify, if accurate, that you must first conduct
API-1 and API-2
       comparability studies and if the FDA accepts such results and determines
that API-1 and
       API-2 are comparable, only then will you be able to conduct the
additional Phase III
       pivotal study using API-2. Further, you also state that your plans will
be discussed at the
       CMC meeting. Clarify, as you do on page 2, that you received a denial
notice from the
       FDA on May 23, 2024 for a CMC meeting.
5.     We note your response to comment 5 and 6. Your pipeline table should
provide one line
       for each product candidate being developed to address a single
indication. The purpose of
       the pipeline table is not to depict the alternative ways you may develop
the same product
       candidate. Currently, your table depicts three lines depicting MCS-2
being developed to
       address BPH/LUTS. Please revise your table to remove two of the lines
depicting MCS-2
       for BPH/LUTS as they are not additional candidates, they are alternative
ways that you
       may attempt to develop MCS-2 for BPH/LUTS. The line item that should be
depicted in
       the table is the one that depicts the method of development you are
actively pursuing with
       the FDA.

       If you are able to rely on trials performed using API-1, it is not
appropriate to include a
       separate line item in your table indicating that you have a separate
product candidate for
       MCS-2 (API-1). If the FDA determines that API-1 and API-2 are
sufficiently comparable
       to rely on the clinical trials performed using API-1, then you may
reflect the completion
       of the successful trials using API-1 in your pipeline table for the line
item depicting the
       development of MCS-2 (API-2). Until the FDA has made that comparability
       determination, such results relating to API-1 relate to a development
pathway that you are
       not currently able to pursue due to the fact that API-1 is currently not
available. Similarly,
       if the new Phase III study using API-2 is successful and you are able to
demonstrate to the
 July 19, 2024
Page 3

       FDA that API-1 and API-2 are sufficiently comparable, then you will be
able to rely on
       the MCS-2-TWN-a study in the pipeline table if you have been able to
re-analyze the data
       from the study to successfully demonstrate to the FDA that it is
reliable.

       We also note your table indicates you are developing PCP (API-1) for
Prostate Cancer in
       Taiwan. Please explain how you are pursuing this using API-1 given that
API-1 is not
       currently available. Alternatively, remove it from your pipeline table.
6.     We note your response to prior comment 8 and reissue our comment. Please
refer to page
       2 of 7 from the FDA correspondence dated 26, 2023 you provided in
response to our
       request on May 31, 2024, which states:
       "Because of the heterogeneous nature of a botanical drug and uncertainty
about its active
       constituents a critical issue for botanical drugs is ensuring that the
therapeutic effect for
       drug batches is consistent. In general, therapeutic consistency can be
supported by a
       'totality of the evidence' approach, including botanical raw material
control, quality
       control, by chemical test(s), manufacturing control, a biological assay
(if needed) and
       clinical data. Seemingly minor changes in the API source and/or
manufacturing process
       may result in a meaningful difference in the clinical effects and raise
concerns about the
       applicability of earlier pharmacological, nonclinical and clinical
data."

       See also pages 2-3 of 10 which states, "any changes (e.g. changes in the
agricultural sites,
       agricultural and collection practices and/or processing/manufacturing
methods) should be
       assessed carefully to determine if the BDS and the botanical drug
product (BDP) batches
       produced after such a proposed change would be sufficiently similar
pharmacologically
       and/or therapeutically to batches prior to such a change."

       Please note the potential impact of these "seemingly minor changes"
apply to changes in
       suppliers of the active pharmaceutical ingredient as well as the change
in the active
       pharmaceutical ingredient provided by the supplier of API-1 prior to its
relocation and
       following its relocation. Therefore, in order to produce MCS-2 using
API-1 following a
       relocation, you would have to demonstrate comparability again. Please
revise your
       disclosure to clarify that if you intend to develop MCS-2 using API-1 if
it becomes
       available, you will have to demonstrate comparability again. If you are
unable to
       demonstrate comparability, you will have to perform more clinical
trials.
7.     Please provide us with a copy of the FDA meeting minutes from your
January 20, 2013
       CMC meeting in which the FDA staff encouraged you to select multiple
vendors for the
       botanical raw material and advised you to identify more raw material
vendors to avoid
       any potential supply shortages in the early stages. The June 26, 2023
FDA
       correspondence you provided indicates that "minor changes in the API
source and/or
       manufacturing process may result in a meaningful difference in the
clinical effects and
       raise concerns about the applicability of earlier pharmacological,
nonclinical and clinical
       data" which appears inconsistent with this advice.
Risk Factors, page 17

8.     Please include a risk factor addressing the possibility that the FDA
does not agree that
       API-1 and API-2 are sufficiently comparable. The discussion should
address the FDA's
       concerns related to changes in agricultural sites, agricultural and
collection practices,
 July 19, 2024
Page 4

       processing and manufacturing methods, etc. and the consequences if the
FDA determines
       that API-1 and API-2 are not sufficiently comparable.
9.     Please include an additional risk factor discussing the FDA's stated
concerns about your
       proposed plan to conduct only one phase 1 study and one phase 3 efficacy
study. The
       discussion should identify the FDA's concerns you will have to address
in order to
       successfully develop MCS-2 (API-2), given your current plan and the
potential
       consequences, if you are unable to demonstrate to the FDA that your
proposal is sufficient
       to demonstrate safety and efficacy.
Leverage differentiated approaches to advance our development..., page 112

10.    In response to prior comment 14 you state you plan to complete all
source data
       verification, database lock and statistical analysis, and draft the
clinical study report. Such
       steps appear necessary for you to advance your product candidate. You
also state on page
       1 that you do not plan to discuss PCP with the TFDA until after you have
conducted
       comparability studies. Please clarify if this process is dependent on
first selecting an API-
       2 supplier and conducting successful comparability studies or if you
will be verifying and
       analyzing the data at the same time you are performing comparability
studies. Please
       clarify that if the comparability studies are not successful, the PCP
clinical trials will have
       to be performed again using PCP (API-2).
Our Drug Candidates
Phase II Clinical Studies, page 118

11.    In response to prior comment 15 we note the additional disclosure
provided under Clinical
       Data and Phase I Clinical Studies. Please also include disclosure under
Phase II and Phase
       III Clinical Studies, on pages 118 and 119 respectively, to state that
if your comparability
       studies are not accepted by the FDA you will need to conduct additional
Phase II and
       Phase III studies to continue your clinical development.
Phase III Clinical Studies, page 119

12.    We note your response to prior comment 16 and reissue in part. Please
clarify here, as you
       do on page 123, that the remaining data you are referring to is the data
from the two Phase
       III studies conducted in Taiwan and the one Phase III US open label
extension study. Also
       include a discussion here and on page 123 that the U.S. FDA has
expressed concerns
       regarding the reproducibility of some of the reported efficacy results
for Study MCS-2-
       TWN-a as you do on page 1.
13.    We note your response to prior comment 17. Specifically, that you will
not need to
       reproduce the Phase III study in US (MCS-2-US-a) if the US FDA has
approved the
       comparability of API-1 and API-2 and the results of an additional Phase
III study (MCS-
       2-US-b) using API-2. Provide the basis for your determination that the
FDA will rely on
       results of trials that failed to demonstrate a difference between the
treatment groups for
       the primary efficacy endpoint in the intent-to-treat population. Please
also include
       additional disclosure stating that if the FDA does not approve your
comparability studies
       you will need to reproduce MCS-2 (API-1) Phase III study in the US
because it failed to
       show a difference between treatment groups for the primary efficacy
endpoint in the
       intent-to-treat population.
 July 19, 2024
Page 5

14.    We note that in response to prior comment 18 you removed the US-a +
TWN-a/ITT
       results from Table 1 and 2. However, we note that your disclosure still
contains
       statements such as "[a]ccording to the results of phase III clinical
trials after pooling US-a
       and TWN-a..." Given your disclosure throughout your prospectus that the
FDA
       determined your Phase III clinical trial in the U.S. failed to show a
difference between the
       treatment groups for the primary efficacy endpoint in the intent-
to-treat population,
       pooling the results masks the different outcomes from the two trials.
Please amend to
       separately present the results of each of the Phase III trials completed
throughout your
       filing.
        Please contact Mary Mast at 202-551-3613 if you have questions
regarding comments on
the financial statements and related matters. Please contact Doris Stacey Gama
at 202-551-3188
or Suzanne Hayes at 202-551-3675 with any other questions.



                                                             Sincerely,

                                                             Division of
Corporation Finance
                                                             Office of Life
Sciences
cc:   Ross Carmel, Esq.
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
